Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Osteoinductivity potential of rhBMP-2 associated with two carriers in different dosages

Full text
Author(s):
Fernandes Abdala, Priscilla Maria [1] ; Iyomasa, Mamie Mizusaki [1] ; Sato, Sandra [2] ; Lopes Badra Bentley, Maria Vitoria [3] ; Pitol, Dimitrius Leonardo [1] ; Hallak Regalo, Simone Cecilio [1] ; Siessere, Selma [1] ; Mardegan Issa, Joao Paulo [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Dept Morphol Oral Med & Physiol, Fac Dent, BR-14040904 Sao Paulo - Brazil
[2] Univ Sao Paulo, Dept Dent Mat & Prosthodont, Fac Dent Ribeirao Preto, BR-14040904 Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: ANATOMICAL SCIENCE INTERNATIONAL; v. 85, n. 4, p. 181-188, DEC 2010.
Web of Science Citations: 7
Abstract

The objective of this study was to evaluate bone formation after application of different doses of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with monoolein or poloxamer gels, in critical bone defects of rats. Forty-five Wistar rats were divided into nine treatment groups with five animals each: I: application of 1 A mu g rhBMP-2 + monoolein; II: 3 A mu g rhBMP-2 + monoolein; III: 7 A mu g rhBMP-2 + monoolein; IV: 1 A mu g rhBMP-2 + poloxamer; V: 3 A mu g rhBMP-2 + poloxamer; VI: 7 A mu g rhBMP-2 + poloxamer; VII: monoolein only; VIII: poloxamer only; and IX: critical bone defect only. A critical-sized defect of 6 mm diameter was produced in the left parietal bone and it was filled with gels of the above mentioned treatments. After 2 weeks, the calvarial bones were removed for histological processing. Bone formation in the groups that received poloxamer gel and rhBMP-2 was not significantly different from the control group (IX). Groups receiving monoolein and rhBMP-2 (1 and 3 A mu g) and those that received only the carriers (VII and VIII) had less bone formation in relation to the control. The association of rhBMP-2 to both poloxamer and monoolein did not exhibit any significant differentiation in bone formation in comparison with the control group. (AU)